Cover Image
Market Research Report

Natural Killer Cell Therapies: Pipeline Review

Published by ROOTS ANALYSIS Product code 858729
Published Content info 80 Pages
Delivery time: 1-2 business days
Price
Back to Top
Natural Killer Cell Therapies: Pipeline Review
Published: June 30, 2019 Content info: 80 Pages
Description

Example Insights:

Presently, over 150 research studies, evaluating various types of NK cell based therapy candidates for oncological indications, are underway.

The NK cell therapy pipeline features both off-the-shelf and personalized therapy candidates, with several leads being developed in combination with other drugs; the contribution of older companies is worth recognizing.

Both North America and Asia are currently leading in terms of number of clinical research initiatives focused on NK cells; the field has an elaborate early stage pipeline with several promising product candidates.

Overview:

Natural killer (NK) cells, or killer (K) cells, represent an important subset of cellular mediators of the innate immune system. These cells are known to be instrumental in containing viral infections and regulating tumor development, while the adaptive immune system generates an antigen-specific response. Technically, they are classified as group I innate lymphocytes. Although they share a common progenitor, NK cells are very different from B-lymphocytes and T-lymphocytes, and do not require specific antigen-based activation in order to function. The cytotoxic effects of these cells are mediated using perforin and granzymes, which is somewhat similar to the mode of action of cytotoxic T cells. Additionally, studies have demonstrated that NK cells can also secrete certain cytokines and chemokines, such as IFNy and TNFα, through which they can recruit other immune components to augment and sustain an immune response. For instance, IFNy secreted by NK cells has been shown to be involved in T-helper (TH1) cell based immune response, and the activation of certain antigen-presenting cells and macrophages. Alternatively, NK cells have been shown to respond to certain types of interferons and macrophage-derived cytokines.

Several studies have demonstrated the various benefits of NK cells as a therapeutic tool. Currently, these cells are being evaluated across multiple clinical trials to treat various types of cancer and infectious diseases. Further, the genetic modification of NK cells has demonstrated additional benefits, and many companies are also working on developing allogenic product candidates that can be used as off-the-shelf therapies.

Scope of the Report:

The “Natural Killer Cell Therapies: Pipeline Review” report features an extensive study of the current market landscape and clinical research scenario related to all NK cell-based products / product candidates. The information in this report has been presented in the form of interactive dashboards, aiming to provide a comprehensive overview of the ongoing activity in this domain, and offering insights on a number of important parameters, including:

  • An analysis of the contemporary developer landscape, providing information on key innovator companies and their respective NK cell therapies, current (highest) phase of development, source of NK cells (autologous and allogenic), target disease indication (hematological malignancies, solid tumors and others), type of therapy (monotherapy and combination therapy), route of administration and other relevant details (if available).
  • Analysis of both completed and active clinical trials, initiated from January 2009, featuring details on (primary) developer company (year of establishment, location of headquarters, and company size), type of developer (industry and non-industry), name of therapy, source of NK cells (autologous and allogenic), and other trial related details (collaborating sponsors, trial title, study objectives, location of trial, current status, availability of results, target therapeutic indication, study type, current / anticipated enrolment, study start / end date and key outcomes / results).
  • Analysis of terminated clinical trials, highlighting the developer company, type of developer (industry and non-industry), name of therapy, source of NK cells (autologous and allogenic), other trial related details (collaborating sponsors, trial title, study objectives, target therapeutic indication and study type) and reason for termination.

All information has been sourced and analyzed from company websites, press releases, reliable clinical trial data repositories (such as clinicaltrials.gov), and other publicly available information platforms.

Dashboard Outlines:

Dashboard 1 is an interactive MS Excel dashboard that provides a detailed review of the contemporary developer landscape, featuring the identities and details of various innovator companies and their respective NK cell therapy candidates. The dashboard offers insights on current (highest) phase of development, source of NK cells (autologous and allogenic), target disease indication (hematological malignancies, solid tumors and others), type of therapy (monotherapy and combination therapy), route of administration and other relevant details (wherever available).

Dashboard 2 is an interactive MS Excel dashboard featuring an analysis of both completed and active clinical trials, which were registered starting from January 2009 to May 2019, featuring detailed charts on (primary) developer company (year of establishment, location of headquarters, and company size), type of developer (industry and non-industry), name of therapy, source of NK cells (autologous and allogenic), and other trial related details (collaborating sponsors, trial title, study objectives, location of trial, current status, availability of results, target therapeutic indication, study type, current / anticipated enrolment, study start / end date and key outcomes / results).

Dashboard 3 is another interactive MS Excel dashboard that offers a retrospective analysis of the various clinical development programs of NK cell based therapies clinical trials that have been discontinue for various reasons (highlighted wherever available). It is worth mentioning that in this analysis we have we have designated the “unknown” status to certain clinical development program that have not been updated from a long time, assuming that such trials are either terminated or indefinitely suspended. The analysis presented in this dashboard has been based on the identity and key details of developer company, (such as type of developer, geographical location), name of therapy, source of NK cells (autologous and allogenic), other trial related details (collaborating sponsors, trial title, study objectives, target therapeutic indication and study type) and reason for termination (wherever available).

Table of Contents

Table of Contents

1. Introduction and Scope

2. Developer Landscape

  • 2A. Developer Landscape: Analysis by Location of Headquarters
  • 2B. Developer Landscape: Analysis by Phase of Development
  • 2C. Developer Landscape: Analysis by Target Disease Indication
  • 2D. Developer Landscape: Analysis by Source of NK Cells
  • 2E. Developer Landscape: Analysis by Type of Therapy
  • 2F. Developer Landscape: Analysis by Route to Administration
  • 2G. Developer Landscape: Analysis by Year of Establishment (Industry Players)
  • 2H. Developer Landscape: Analysis by Company Size (Industry Players)

3. Completed and Active Trials

  • 3A. Clinical Trial Analysis: Analysis by Current Trial Status
  • 3B. Clinical Trial Analysis: Analysis by Phase of Development
  • 3C. Clinical Trial Analysis: Analysis by Availability of Results
  • 3D. Clinical Trial Analysis: Analysis by Target Disease Indication
  • 3E. Clinical Trial Analysis: Analysis by Source of NK Cells
  • 3F. Clinical Trial Analysis: Analysis by Type of Therapy
  • 3G. Clinical Trial Analysis: Analysis by Study Type
  • 3H. Clinical Trial Analysis: Analysis of Enrolled Patient Population
  • 3I. Clinical Trial Analysis: Analysis by Study Start / End Dates
  • 3J. Geographical Location of Primary Sponsor
  • 3K. Geographical Location of Completed / Active Trials

4. Terminated Trials

  • 4A. Terminated Trials: Analysis by Reason for Termination
  • 4B. Terminated Trials: Analysis by Phase of Development
  • 4C. Terminated Trials: Analysis by Target Disease Indication
  • 4D. Terminated Trials: Analysis by Source of NK Cells
  • 4E. Terminated Trials: Analysis by Type of Therapy
  • 4F. Terminated Trials: Analysis by Study Type

5. Appendix I: Dataset 1: Developer Landscape

6. Appendix II: Dataset 2: Completed / Active Clinical Research Trials

7. Appendix III: Dataset 3: Terminated Clinical Research Trials

8. Appendix IV: Dataset 4: Clinical Research, 2009-2019

9. Abbreviations

10. Sources and Bibliography

List of Figures

  • Figure 2.1. Developer Landscape: Distribution by Location of Headquarters
  • Figure 2.2. Developer Landscape: Distribution by Phase of Development
  • Figure 2.3. Developer Landscape: Distribution by Target Disease Indication
  • Figure 2.4. Developer Landscape: Distribution by Source of NK Cells
  • Figure 2.5. Developer Landscape: Distribution by Type of Therapy
  • Figure 2.6. Developer Landscape: Distribution by Route to Administration
  • Figure 2.7. Developer Landscape: Distribution by Year of Establishment (Industry Players)
  • Figure 2.8. Developer Landscape: Distribution by Company Size (Industry Players)
  • Figure 3.1. Clinical Trial Analysis: Distribution by Current Trial Status
  • Figure 3.2. Clinical Trial Analysis: Distribution by Phase of Development
  • Figure 3.3. Clinical Trial Analysis: Distribution by Availability of Results
  • Figure 3.4. Clinical Trial Analysis: Distribution by Target Disease Indication
  • Figure 3.5. Clinical Trial Analysis: Distribution by Source of NK Cells
  • Figure 3.6. Clinical Trial Analysis: Distribution by Type of Therapy
  • Figure 3.7. Clinical Trial Analysis: Distribution by Study Type
  • Figure 3.7. Clinical Trial Analysis: Distribution of Enrolled Patient Population
  • Figure 3.7. Clinical Trial Analysis: Distribution by Study Start / End Dates
  • Figure 3.8. Geographical Location of Primary Sponsor
  • Figure 3.9. Geographical Location of Completed / Active Trials
  • Figure 4.1. Terminated Trials: Distribution by Reason for Termination
  • Figure 4.2. Terminated Trials: Distribution by Phase of Development
  • Figure 4.3. Terminated Trials: Distribution by Target Disease Indication
  • Figure 4.4. Terminated Trials: Distribution by Source of NK Cells
  • Figure 4.5. Terminated Trials: Distribution by Type of Therapy
  • Figure 4.6. Terminated Trials: Distribution by Study Type

Listed Companies and Organizations

The following companies and organizations have been mentioned in the report.

  • 1. Allife Medical Science and Technology
  • 2. Anhui Provincial Hospital
  • 3. Asan Medical Center
  • 4. Baylor College of Medicine
  • 5. Capital Medical University
  • 6. Case Comprehensive Cancer Center
  • 7. Catholic University of Korea
  • 8. Cell Medica
  • 9. CellProtect Nordic Pharmaceuticals
  • 10. Celularity
  • 11. Chinese PLA General Hospital
  • 12. CiMass
  • 13. Cyto-Sen Therapeutics
  • 14. Cytovac
  • 15. Dresden University of Technology
  • 16. Duke University
  • 17. Fate Therapeutics
  • 18. First Hospital of Jilin University
  • 19. Fortress Biotech
  • 20. Fuda Cancer Hospital
  • 21. Gamida Cell
  • 22. GC PharmaGreen Cross Corporation
  • 23. Glycostem Therapeutics
  • 24. Gregorio Marañón Hospital
  • 25. Gruppo Italiano Malattie EMatologiche dell'Adulto
  • 26. Guangdong Provincial Hospital of Traditional Chinese Medicine
  • 27. Guangzhou Medical University
  • 28. Hangzhou Cancer Hospital
  • 29. Harbin Medical University
  • 30. Henan Cancer Hospital
  • 31. Hospital of Clinics of Porto Alegre
  • 32. Hospital Universitario La PazHospital La Paz
  • 33. iCell Gene Therapeutics
  • 34. Italian Group Hematological Diseases of the Adult
  • 35. Italian Sarcoma Group
  • 36. Ivy Life Sciences
  • 37. M.D. Anderson Cancer Center
  • 38. Mayo Clinic
  • 39. Medical College of Wisconsin
  • 40. Memorial Sloan Kettering Cancer Center
  • 41. Multimmune
  • 42. NantKwest
  • 43. National Cancer Institute
  • 44. National Defense Medical Center
  • 45. National University Hospital
  • 46. Niño Jesús University Children's HospitalHospital Niño Jesus
  • 47. Nkarta Therapeutics
  • 48. Nohla Therapeutics
  • 49. Paoli-Calmettes Institute
  • 50. PersonGen BioMedicineTherapeutics
  • 51. Pope John XXIII HospitalA.O. Ospedale Papa Giovanni XXIII
  • 52. Public Assistance - Hospitals of Paris
  • 53. Radboud University
  • 54. Sabz Biomedicals
  • 55. Samsung Medical Center
  • 56. Seoul National University Hospital
  • 57. Shanghai Houchao Biotechnology
  • 58. Shanghai iCELL Biotechnology
  • 59. Shanghai Public Health Clinical Center
  • 60. Shenzhen Hornetcorn Bio-technology Company
  • 61. Shenzhen Second People's Hospital
  • 62. SMT Bio
  • 63. Southwest Medical UniversityHospital, China
  • 64. St. Jude Children's Research Hospital
  • 65. Stanford University
  • 66. Sun Yat-sSen University
  • 67. Surface Oncology
  • 68. Tanta University
  • 69. The Catholic University of Korea
  • 70. The First People's Hospital of Changzhou
  • 71. University Hospital of, Basel
  • 72. University Hospital ofin Besançon
  • 73. University of Arkansas
  • 74. University of Minnesota
  • 75. University of Wisconsin
  • 76. Washington University School of Medicine
  • 77. Xuanwu Hospital
  • 78. Xuzhou Medical University
  • 79. Yonsei University
  • 80. Zumutor Biologics
Back to Top